News | October 23, 2006

Ablation Superior to Amiodarone for the Treatment of First-Episode Symptomatic Atrial Flutter

Radiofrequency ablation is more effective than treatment with amiodarone for the prevention of atrial flutter recurrence in patients who experienced a first symptomatic episode, according to the results of a new study. In addition to the superiority of ablation over amiodarone, there was no increased risk of atrial fibrillation, even in this cohort of older patients, report investigators.

"Based on the registry of clinical studies using radiofrequency ablation to treat atrial flutter, we knew that the percentage of recurrence was very low with ablation and that the number of secondary effects was also very low," lead investigator Dr. Antoine Da Costa (University Jean Monnet, Saint Etienne, France) told heartwire. "Looking at the recurrence rates or the secondary effects with drug treatment, we believed that ablation would fare better, although no there were no studies showing this to be the case. With the number of secondary effects with amiodarone and the percentage of recurrence, compared with radiofrequency ablation, there is clear clinical evidence that radiofrequency ablation is better."

Publishing the findings in the Oct. 17, 2006 issue of Circulation, Dr. Da Costa and colleagues suggest that "radiofrequency ablation should be considered as first-choice therapy even after the first episode of symptomatic atrial flutter."

Despite the positive results, Dr. D George Wyse (University of Calgary, Alberta), who wrote an editorial accompanying the published study, suggests that the efficacy of ablation in preventing the recurrence of atrial flutter as well as the emergence of atrial fibrillation, might be attributable to trial design rather the true differences.

"The major issue is that events contributing to the end points were accumulated during a time in which radiofrequency ablation would be expected to be efficacious but amiodarone would not," writes Wyse. "In a more general sense, it is time that trials of radiofrequency ablation for the treatment of atrial flutter/atrial fibrillation move on from testing the simpler question of antiarrhythmic efficacy to testing the treatment using robust and clinically relevant end points. Although testing for antiarrhythmic efficacy is important at the beginning, perhaps we are nearing the end of the beginning."

Related Content

First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Overlay Init